SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Transposon Therapeutics, a biotechnology company developing therapies for the treatment of neurodegenerative and aging-related diseases, today announced ...
TPN-101 is the First PSP Treatment to Reduce NfL and IL-6 Levels, Key Biomarkers of Neurodegeneration and Neuroinflammation in PSP SAN DIEGO, May 21, 2024 /PRNewswire/ -- Transposon Therapeutics, a ...
The company's lead clinical compound, TPN-101, is first-in-class to address LINE-1 reverse transcriptase for treating neurodegenerative and autoimmune diseases. The company also has a discovery ...
24-Week data show TPN-101 is the first treatment for PSP to reduce NfL levels, a key biomarker of neurodegeneration in tauopathies such as PSP and Alzheimer's disease TPN-101 also showed a reduction ...
ARPA-H PROSPR program to support the development of TPN-101 to slow aging and help people stay healthy longer SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Transposon Therapeutics, a biotechnology ...
(MENAFN- GlobeNewsWire - Nasdaq) ARPA-H PROSPR program to support the development of TPN-101 to slow aging and help people stay healthy longer SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Transposon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results